Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2015 Apr 23

PMID 25899862

Authors

Partow Kebriaei

Michelle Limei Poon

Affiliations

Soon will be listed here.

Abstract

The prognosis of acute lymphoblastic leukemia (ALL) in adults remains poor, and novel treatment options are needed to improve outcomes. Immunotherapeutic strategies have been a recent focus in this area, targeting specific surface antigens on the ALL blast cells. Our review concentrates on four major class of antibody therapies, namely, (1) naked and unconjugated antibodies, (2) immunoconjugates and immunotoxins, (3) bi-specific T cell engaging (BiTE) therapy, and (4) chimeric antigen receptor (CAR) expressing T cells. We review preclinical and clinical data, and update on the latest advances in this exciting field, and suggest how these therapies can be incorporated into the treatment algorithm for ALL.

References

Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M . Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012; 13(4):403-11. DOI: 10.1016/S1470-2045(11)70386-2. View

Maury S, Huguet F, Leguay T, Lacombe F, Maynadie M, Girard S . Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. 2009; 95(2):324-8. PMC: 2817037. DOI: 10.3324/haematol.2009.010306. View

Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S, Braunchweig I . A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol. 2011; 154(4):471-6. PMC: 3877839. DOI: 10.1111/j.1365-2141.2011.08762.x. View

Advani A, McDonough S, Coutre S, Wood B, Radich J, Mims M . SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014; 165(4):504-9. PMC: 4209396. DOI: 10.1111/bjh.12778. View

Thomas X, Boiron J, Huguet F, Dombret H, Bradstock K, Vey N . Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004; 22(20):4075-86. DOI: 10.1200/JCO.2004.10.050. View

Mussai F, Campana D, Bhojwani D, Stetler-Stevenson M, Steinberg S, Wayne A . Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol. 2010; 150(3):352-8. PMC: 7316383. DOI: 10.1111/j.1365-2141.2010.08251.x. View

Kantarjian H, Thomas D, Wayne A, OBrien S . Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol. 2012; 30(31):3876-83. PMC: 3478578. DOI: 10.1200/JCO.2012.41.6768. View

Topp M, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S . Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(36):4134-40. DOI: 10.1200/JCO.2014.56.3247. View

Topp M, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S . Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011; 29(18):2493-8. DOI: 10.1200/JCO.2010.32.7270. View

10.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

11.

Jensen M, Popplewell L, Cooper L, DiGiusto D, Kalos M, Ostberg J . Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010; 16(9):1245-56. PMC: 3383803. DOI: 10.1016/j.bbmt.2010.03.014. View

12.

Kantarjian H, Thomas D, OBrien S, Cortes J, Giles F, Jeha S . Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101(12):2788-801. DOI: 10.1002/cncr.20668. View

13.

Thomas D, OBrien S, Jorgensen J, Cortes J, Faderl S, Garcia-Manero G . Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2008; 113(25):6330-7. PMC: 2943753. DOI: 10.1182/blood-2008-04-151860. View

14.

Chevallier P, Huguet F, Raffoux E, Etienne A, Leguay T, Isnard F . Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. Haematologica. 2015; 100(4):e128-31. PMC: 4380733. DOI: 10.3324/haematol.2014.120220. View

15.

Wei H, Xiang L, Wayne A, Chertov O, Fitzgerald D, Bera T . Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc Natl Acad Sci U S A. 2012; 109(18):6898-903. PMC: 3345006. DOI: 10.1073/pnas.1204523109. View

16.

Advani A, Coiffier B, Czuczman M, Dreyling M, Foran J, Gine E . Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010; 28(12):2085-93. DOI: 10.1200/JCO.2009.25.1900. View

17.

Kebriaei P, Saliba R, Ma C, Ippoliti C, Couriel D, de Lima M . Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant. 2006; 38(3):203-9. DOI: 10.1038/sj.bmt.1705425. View

18.

Kebriaei P, Wilhelm K, Ravandi F, Brandt M, de Lima M, Ciurea S . Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013; 13(3):296-301. PMC: 4102410. DOI: 10.1016/j.clml.2012.12.003. View

19.

Jeune C, Thomas X . Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. Eur J Haematol. 2014; 94(2):99-108. DOI: 10.1111/ejh.12408. View

20.

Tibes R, Keating M, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G . Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006; 106(12):2645-51. DOI: 10.1002/cncr.21901. View